公开(公告)号：US20230220012A1

公开(公告)日：2023-07-13

申请号：US17998729

申请日：2021-05-13

Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY

Inventor： Seong Jun KIM ,  Chonsaeng KIM ,  Kyun Do KIM ,  Dae Gyun AHN ,  Young Chan KWON ,  Keunbon KU ,  Hae Soo KIM ,  Hye Jin SHIN ,  Gun Young YOON ,  In Su HWANG ,  Gi Uk JEONG ,  Sun Hee LEE ,  Mi Hwa KIM ,  Su Min LEE ,  Bum Tae KIM

IPC: C07K14/005 ,  A61K39/215 ,  A61P31/14

CPC classification number: C07K14/005 ,  A61K39/215 ,  A61P31/14 ,  C12N2770/20022 ,  C12N2770/20034 ,  C07K2319/03

Abstract: Provided are a recombinant antigen comprising a cell membrane permeation domain comprising a polypeptide of any one of SEQ ID NOs: 1 to 22 derived from human LRRC24 and a SARS-CoV-2 antigen or a fragment thereof, a vaccine composition comprising the recombinant antigen, a gene construct comprising a polynucleotide encoding the recombinant antigen, a recombinant vector comprising the gene construct, a method for producing the SARS-CoV-2 recombinant antigen, and a kit for preventing or treating SARS-CoV-2 infection comprising the vaccine composition and users' instruction thereof, wherein the antigen exhibited higher immunogenicity against SARS-CoV-2 the neutralizing antibody was better formed in actual animal experiments, excellent protective immunity was induced, and toxicity did not appear in the toxicity test.

公开(公告)号：US20220306718A1

公开(公告)日：2022-09-29

申请号：US17296622

申请日：2019-12-16

Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY

Inventor： Seong Jun KIM ,  Kyun Do KIM ,  In Su HWANG ,  Keunbon KU ,  Chonsaeng KIM ,  Bum Tae KIM ,  Dae Gyun AHN ,  Hae Soo KIM ,  Young Chan KWON

IPC: C07K14/705 ,  A61K47/64

Abstract: The present invention relates to a transmembrane domain derived from human LRRC24 protein. More specifically, the present invention relates to a transmembrane domain derived from the human LRRC24 protein (LRRC24P transmembrane domain) or a cell-penetrating peptide, and an intracellular delivery system comprising same. The transmembrane domain derived from the human LRRC24 protein of the present invention can be used to deliver cargo materials such as compounds, biomolecules, and various polymer materials into cells. Since the LRRC24P transmembrane domain of the present invention exhibits higher cell penetration efficiency compared to conventional cell-penetrating peptides and is derived from human proteins, thus avoiding side effects and immune responses caused by peptides derived from foreign proteins, it can be usefully used as an effective intracellular delivery method for compounds, biomolecules, and various polymer materials applied to the human body.